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Introduction
Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers, and its overall 5-year survival rate is only 17% (1) . Approximately 65-75% of patients with NSCLC possess unresectable advanced or metastatic disease at diagnosis (2) . The overall response rate for platinum-based therapy, which is the standard of care for these patients, ranges between 17% and 32% (3), with a median survival time of only 7-9 months (4). The current challenge posed by the rather short survival time in patients with advanced NSCLC demands the discovery of new biomarkers that enable prediction of survival time and categorization of different prognostic groups, thereby enabling health care providers to personalize treatment and helping patients to manage expectations effectively.
Alterations in miRNA expression have been known to affect multiple cellular processes, including cell differentiation, cell cycle progression, and apoptosis (5) (6) (7) . It has been clearly demonstrated that miRNAs are of potential clinical relevance and possess enormous promise to serve as novel biomarkers in cancer diagnosis and prognosis (8) (9) (10) . Stable existence of cell-free miRNA in plasma/serum has been repeatedly demonstrated in numerous studies (11) (12) (13) , and alterations in miRNA profiles or expression levels are potentially indicative of physiological and pathological change. A number of studies have demonstrated the potential of miRNAs in plasma/serum as biomarkers for specific cancer diagnosis and prognosis (14) . In this study, we aimed to identify potential serum miRNA biomarkers for predicting patient survival in advancedstage NSCLC. We demonstrate that expression levels of selected serum miRNAs are significantly associated with patient survival.
To focus on serum miRNAs associated with the cancer signaling network, we utilized a pathway-based miRNA profiling approach, specifically focusing on the transforming growth volume, one patient with >10 years of serum storage, 17 patients with serum samples collected after treatment started, 201 newly recruited patients with demographic and clinical data yet to be input into database at the time of sample selection, and 22 patients lost to follow-up prior to 2 years. Among the remaining 807 patients, 484 patients had their serum samples stored in Cryo vials and the other 323 serum samples were stored in MAPI straws (Cryo Bio System). To minimize the effect of serum storage condition on miRNA expression, we only used the 484 samples stored in Cryo vials. After excluding 29 patients with hemolyzed serum samples upon visual determination and 64 patients without sufficient serum RNA concentration after isolation, 391 patients were included in our final dataset. Comparisons of the patients included in this study to the overall study population of 1,060 showed no differences by basic demographic and clinical data distribution including age, gender, smoking status, disease stage, histology, grade, performance status and treatment regimens, except that patients included in this study had a slightly high death rate. This would be expected given that the majority of excluded patients were recently recruited patients who were still alive and did not have sufficient follow-up time.
Study approval was obtained from the MD Anderson Institutional Review Board.
The initial global miRNA screening included eight Caucasian patients, four with good survival (survival time >24 months) and four with poor survival (survival time <6 months), matched by age, sex, histological stage, and smoking status (Figure 1) . Assignment of the 383 samples to the training and testing populations was performed by sorting the samples by enrollment date and then distributing in an alternating manner (Table 1) .
Total RNA Isolation
Total RNA was isolated from serum samples using the miRNeasy Mini Kit (Qiagen) following the manufacturer's protocol. For whole-genome miRNA profiling, 700 μL serum was used for 6 RNA isolation, and for qRT-PCR assay, the serum amount was reduced to 400 μL. Synthetic celmiR-39 and cel-miR-54 were added to each sample as internal controls for evaluation of successful extraction. RNAs were eluted twice with 30 μL of water. The total concentration of small RNA molecules was quantified by NanoDrop ND-1000 spectrometer (Thermo Scientific, DE). To minimize any potential inaccuracies generated by the Nanodrop measurements, we carefully kept consistent the amount of serum samples and spike-in miRNAs prepared from the same batch for isolation -throughout all experiments. In addition, the raw Ct value for each miRNA was normalized to the raw Ct value for spike-in miRNAs obtained from each individual sample to eliminate potential variations introduced from the isolation process and RNA quantification. To eliminate potential hemolysis-introduced miRNA bias, 30 serum samples were random selected and tested for free hemoglobin levels on VITROS 
Selection of TGF-β Signaling Pathway Related Serum MiRNAs
Whole-genome serum miRNA profiling was performed on the eight serum samples using the TaqMan Human MicroRNA Microarray Card Set v3.0 (Applied Biosystems, CA). In brief, purified serum RNA samples were reverse-transcribed using Megaplex RT Primers followed by a pre-amplification step using Megaplex PreAmp Primers for maximum sensitivity of detection.
For final quantification, the TaqMan Universal Master Mix II was added, and each sample was loaded on the MicroRNA Microarray Cards. Quantitative PCR was performed on the 7900HT Fast Real-Time PCR System (Applied Biosystems). The expression threshold for each miRNA detector was automatically determined. A miRNA candidate was considered highly expressed when over 75% of samples in both study groups generated detectable Ct values of less than 35. To identify miRNA candidates associated with the TGF-β signaling pathway, a total of 23 candidate genes were selected utilizing Gene Ontology (http://www.geneontology.org) and the National Center for Biotechnology Information (NCBI) PubMed (http://www.ncbi.nlm.nih.gov) databases as previously described (17) . MiRNAs potentially binding these candidate genes were predicted by TargetScanHuman v5.2 (www.targetscan.org) (18) , and miRNAs associated with the binding sites broadly conserved among vertebrates with higher probability of preferential scores (19) were considered for further analysis.
Quantitative Real-Time PCR Assay
Selected miRNAs were tested using individual TaqMan MiRNA Assays (Applied Biosystems) to quantitatively measure the difference in their expression levels between patient groups with varied survival times. Each assay was tested in duplicates. Data points that generated duplicated Ct values with over one cycle variance were excluded from analysis.The mean Ct value obtained from each sample was normalized to the averaged expression of spike-in miRNAs and then subjected to analysis with the 2 -ΔΔCt method (20) .
Statistical Analysis
Statistical analyses were performed using Intercooled STATA software, version 10 (College Station, TX). χ2 analysis was used to evaluate differences in patient characteristics. Survival time was calculated from the date of study enrollment to the date of death or last patient followup. The median time between diagnosis of NSCLC and study enrollment (date of blood draw) was 24 days. Rank sum test was used to assess differences in median miRNA expression levels between stage III and stage IV patients. The associations between 2-year survival and serum miRNA expression levels were estimated as hazard ratios (HRs) and 95% confidence intervals (CIs) for each miRNA using the Cox proportional hazards model, adjusted for age, sex, smoking (21) . All patients were dichotomized by the median risk score, and individuals with a risk score higher or lower than the median were classified as high or low risk groups, respectively. The optimized statistical method, C-index was utilized to evaluate predictive accuracy of 2-year survival (22) .
Results

Patient Characteristics
A total of 391 Caucasian patients with advanced NSCLC were included in the analysis that covered a broad range of follow-up and survival times (Table 1) . For the initial global miRNA screening using eight samples, survival times in the poor-and good-survival groups ranged from 2.47 to 3.82 months and from 24.61 to 65.23 months, respectively. For the overall patient study population, there was no significant difference between the training set and testing set with respect to vital status, sex, smoking status, performance status, TNM stage, or histology distribution (Table 1) . A slight difference was seen between the two populations in terms of age, which however, was adjusted in subsequent analysis. At the time of analysis, 326 (85.1%) patients had died and 57 (14.9%) were still alive, all of which had survived for over two years.
Whole-Genome Serum MiRNA Profiling
In the combined pool of 754 human miRNAs, excluding endogenous controls and low-quality data points, 166 and 171 serum miRNAs were identified to be highly expressed in the poor-and good-survival groups, respectively, with 140 serum miRNAs were highly expressed in both Table S2 ). In addition, it was noteworthy that one of the candidates, miR-30d, was one of the four biomarkers previously identified to be predictive of survival in early-stage NSCLC (27) .
Association of Serum MiRNA Expression with NSCLC Survival
The 35 candidate miRNAs were assessed for association with survival duration. In the training set, expression levels of 25 serum miRNAs were significantly associated with 2-year survival using the median expression levels as analysis cutoff (data not shown). When the same cutoffs were applied to the testing set, 17 out of 25 miRNAs remained significant with the same direction of effect ( Table 2 ). The results showed that higher expression levels (above the median value) of these 17 serum miRNAs were significantly associated with higher probability of 2-year survival in both the training and testing sets using the same cutoff points. MiR-16 presented the most significant result: in the combined dataset analysis, the 2-year survival rate in the highexpression group reached 37.9%, whereas only 3 of 174 patients (1.7%) in the low-expression group survived over 2 years, with an adjusted HR of 0.4 (95% CI: 0.3-0.5), and a P value of 1.7×10 -10 . The MST advantage in the high-expression group compared with the low-expression group ranged from 2.8 months to 11.5 months among these 17 serum miRNAs (Figure 2A ). Table S3 ). Among these 11 miRNAs, 9 were overlapping with the significant miRNAs associated with survival (Table 2 ). We included stage as an adjustment factor in our analysis of 2-year survival.
Association of Serum MiRNA Expression with NSCLC Stage
Prediction of NSCLC Survival by 17-miRNA Risk Score
The combined effects of these single serum miRNAs significantly associated with survival were investigated by calculating a risk score using the linear combination of expression levels of these 17 miRNAs for each individual on the training data set (Table 3 ). When the same cutoff was applied to the testing set, similar to the training set, patients with high-risk scores exhibited significantly increased risk of death compared to those with low-risk scores (HR=2.71 , 95% CI, 1.65-4.45) ( Table 3 ). The corresponding risk of death in the combined dataset was 2.46 (95% CI, 1.77-3.44). Kaplan-Meier 2-year survival curve showed that patients with the high risk scores had a MST of 7.8 months compared to 15.6 months in the low risk group ( Figure 2B ).
The prognosis values of 2-year survival were expressed as C-index with 100 times of bootstrap in the training, testing and combined datasets (Table 4 ). In the combined dataset, the C- (Table 4) . 
as a prognosis marker for overall survival (33) . In addition, several studies on associations between circulating miRNA levels and lung cancer stages have been reported (37) (38) (39) . A study on plasma miRNA indicated that plasma miR-30e-3p was significantly higher in NSCLC patients with non-resectable tumor compared to those with resectable tumor; but in patients with resectable tumors only, high level of plasma miR-30e-3p was associated with a higher rate of disease free survival (30) . Overall, the results of these studies have been inconsistent, due to small sample size and heterogeneous patient population.
Our current study was one of the largest in NSCLC and we focused on stage III and IV NSCLC patient. We adopted the pathway-based approach and focused our investigation on miRNAs related with genes in the TGF-β signaling pathway. Our study was designed to include an internal validation by distributing the entire population into a training set and a testing set, from where consistent results were obtained. For survival analysis, we identified serum miRNAs that predicted 2-year survival using Cox regression model (Table 2 ). Notable differences in survival times were identified for the patients. Having the ability to better predict prognosissurvival benefits greater than 9 months to a year -could be critical in treatment selection and end-of-life management for advanced-stage patients who are typically given a dismal prognosis.
MiR-16 expression showed the most significant association with 2-year survival in our study. A recent study on resected stage I-III NSCLC tumors revealed the association of high level miR-16 expression with poor prognosis including disease-free survival and overall survival (40); Our current study was the first to report serum miR-16 in association with advanced stage NSCLC survival. We also showed an MST advantage of 11.1 months in patients with high serum levels of miR-30e-3p in contrast to those with low levels. These results were consistent with previously reported findings that plasma miR-30e-3p was associated with favorable disease-free survival (30) . In addition, our results highlighted the significance of the let-7 family, one of the most studied tumor suppressor miRNA families involved in lung cancer, with consistent upregulation observed in tissues for those with a favorable survival (10, 23, 41) . Several other tissue-based investigations have also suggested miR-20 and miR-106a (41) as lung cancer prediction factors, which was consistent with our results in serum.
In addition to individual miRNA analysis, we also evaluated the collective prognosis value of multiple miRNAs by creating a risk score analysis for the 17 identified TGF-β pathway-enriched miRNAs that were significantly associated with 2-year survival. When the patient population was stratified by this combined risk score, a notable, highly significant MST advantage of 7.8 months was observed between the low risk group and the high risk group. To quantitatively present the prognosis power of the 17-miRNA risk score, the C-index for survival prediction of the study population was increased to 0.69 when the risk score was additionally included into the model, compared to 0.64 when only age, gender and smoking status and stage were included.
Additional biomarkers are needed to further improve the prediction efficiency for clinical applications.
There were a few limitations in our study. First, the cellular pathways are redundant and are often co-regulated. It is possible that our results based on the TGF-β pathway and the miRNA- come from other origins such as inflammatory cells, endothelium cells or blood cells. For example, previous studies on circulating miRNAs have suggested the effect of hemolysis on specific miRNA (e.g., miR-16) expression, which may limit the potential utility of these miRNAs in the clinical setting (42) . To address this issue, we measured hemoglobin levels in 30 randomly selected serum samples (10 each from the low, medium and high survival groups). In all the samples tested, the hemoglobin levels were below 15 mg/dL, lower than the previously reported level of 25 mg/dL that started to affect the measurement of serum miRNA (42), suggesting the confounding effect of hemolysis in this current study is minimal. Third, we employed TargetScan to focus on prediction of the canonical 3'UTR miRNA binding; however, non-canonical miRNA binding sites in the coding and other regions are also capable of regulating gene expression (43) (44) (45) (46) (47) (48) (49) . Future studies that include non-canonical miRNA binding sites would complement our current analysis. Finally, although we divided our sample set into a training and testing set, potential systematic biases still could be present in the sample set because the same overall cohort was used. Validation of our reported miRNA candidates in an independent external patient cohort is warranted.
In conclusion, our study was built on a large population of 391 advanced-stage NSCLC cases, which were distributed into three datasets for qualitative whole-genome serum miRNA profiling using a small-scale discovery set, followed by individual qRT-PCR assay evaluation on a training set and a testing set. Seventeen serum miRNAs were able to predict 2-year survival in an analysis using the continuous model, and a risk score was constructed based on these 17 miRNAs, which would potentially predict 2-year survival for late-stage NSCLC patients. If validated in an independent population, these serum miRNAs are promising to be utilized as 
